Cost-effectiveness of Catheter-based Radiofrequency Renal Denervation for Uncontrolled Hypertension
Author Information
Author(s): Sharp Andrew S P, Cao Khoa N, Esler Murray D, Kandzari David E, Lobo Melvin D, Schmieder Roland E, Pietzsch Jan B
Primary Institution: University Hospital of Wales and Cardiff University
Hypothesis
Is catheter-based radiofrequency renal denervation a cost-effective treatment for uncontrolled hypertension in the UK?
Conclusion
Catheter-based radiofrequency renal denervation can be a cost-effective strategy for uncontrolled hypertension in the UK.
Supporting Evidence
- RF RDN resulted in a relative risk reduction in clinical events over 10 years.
- The incremental cost-effectiveness ratio (ICER) was evaluated against the NICE cost-effectiveness threshold.
- Findings were robust across tested scenarios.
- RF RDN added 0.35 QALYs at a cost of £4763.
Takeaway
This study shows that a new treatment for high blood pressure can save money and help people live longer and healthier lives.
Methodology
A decision-analytic model was used to project clinical events, quality-adjusted life years (QALYs), and costs based on multivariate risk equations.
Potential Biases
Potential variability in treatment effect among different demographics and comorbidities.
Limitations
The model does not capture repeat clinical events or a broader range of cardiovascular sequelae.
Participant Demographics
Participants were, on average, 55 years old with a baseline office systolic blood pressure of 163 mmHg.
Statistical Information
P-Value
4.9 mmHg
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website